Production (Stage)
Gemina Laboratories Ltd.
GLAB
CNSX
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -59.79% | 143.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -49.61% | 63.20% | |||
| Operating Income | 50.39% | -63.20% | |||
| Income Before Tax | 46.46% | -57.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 46.46% | -57.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 46.46% | -57.97% | |||
| EBIT | 50.39% | -63.20% | |||
| EBITDA | 50.46% | -63.46% | |||
| EPS Basic | 47.76% | -57.65% | |||
| Normalized Basic EPS | 48.24% | -60.38% | |||
| EPS Diluted | 47.76% | -57.65% | |||
| Normalized Diluted EPS | 48.24% | -60.38% | |||
| Average Basic Shares Outstanding | 2.15% | 0.38% | |||
| Average Diluted Shares Outstanding | 2.15% | 0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||